Latanoprost Ingen Pharma

Latanoprost, the active ingredient in Latanoprost Ingen Pharma, is a prostaglandin analog presented as a eye drops for ocular use. It treats primary open-angle glaucoma and ocular hypertension by lowering intra‑ocular pressure.

GNH USA supplies Latanoprost Ingen Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure.

Primary open-angle glaucoma: lowers intra‑ocular pressure to slow visual field loss. Ocular hypertension: reduces pressure to prevent progression to glaucoma. Secondary open-angle glaucoma (including pseudoexfoliative glaucoma): provides pressure reduction similar to primary forms.

Latanoprost may cause ocular and peri‑ocular changes, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation or foreign body sensation. - Blurred vision: transient after instillation. - Periocular skin darkening: mild hyperpigmentation.

Serious or Rare Side Effects: - Uveitis or severe eye inflammation. - Allergic reactions: swelling, itching, or rash. - Macular edema: fluid accumulation in the retina. - Ocular pain: persistent discomfort. - Vision loss: rare but severe impairment. - Severe hypersensitivity: anaphylactic response.

Before using Latanoprost, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown excretion; use with caution. Active ocular infection: contraindicated until infection resolves. Intra‑ocular pressure monitoring: regular checks recommended to assess efficacy. Contact lens wearers: remove lenses before instillation and wait before reinserting. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents; monitor accordingly.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish pressure‑lowering effect. - Concurrent prostaglandin analogs: risk of additive ocular side effects. - Systemic prostaglandin analogs: potential additive pressure reduction. - Alpha‑adrenergic agonist eye drops: may antagonize Latanoprost efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effect. - Carbonic anhydrase inhibitor eye drops: possible enhanced pressure reduction. - Systemic carbonic anhydrase inhibitors: watch for excessive IOP lowering.